• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Aethlon Medical Inc.

    5/15/24 9:27:15 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care
    Get the next $AEMD alert in real time by email
    POS AM 1 aethlon_posam1.htm AMENDMENT NO 1

    Registration No. 333-278188

     

    As filed with the Securities and Exchange Commission on May 15, 2024

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    Post-effective Amendment No. 1

    To

    FORM S-1

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    Aethlon Medical, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Nevada   3826   13-3632859

    (State or other jurisdiction of

    incorporation or organization)

     

    (Primary Standard Industrial

    Classification Code Number)

     

    (I.R.S. Employer

    Identification Number)

     

    11555 Sorrento Valley Road, Suite 203

    San Diego, CA 92121

    (619) 941-0360

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

     

     

    James B. Frakes

    Interim Chief Executive Officer

    Aethlon Medical, Inc.

    11555 Sorrento Valley Road, Suite 203

    San Diego, CA 92121

    (619) 941-0360

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

     

    Copies to:

         

    Julie Robinson

    Wade Andrews

    Cooley LLP

    10265 Science Center Drive

    San Diego, CA 92121

    (858) 550-6000

     

    M. Ali Panjwani

    Pryor Cashman LLP

    7 Times Square

    New York, NY 10036-6569

    Telephone: (212) 326-0846

    Fax: (212) 326-0806

     

     

     

    Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering.  ☒ 333-278188

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

     

    Large accelerated filer   ☐   Accelerated filer   ☐
           
    Non-accelerated filer   ☒   Smaller reporting company   ☒
           
            Emerging growth company   ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     

    The Registration Statement shall become effective upon filing in accordance with Rule 462(d) promulgated under the Securities Act of 1933, as amended.

     

     

     

     

       

     

     

    EXPLANATORY NOTE

     

    This Post-Effective Amendment No. 1 (“Amendment No. 1”) to the Registration Statement on Form S-1, as amended (File No. 333-278188), declared effective by the Securities and Exchange Commission on May 15, 2024 (“Registration Statement”), is being filed solely for the purpose of replacing Exhibits 5.1 and 5.2 to the Registration Statement. This Amendment No. 1 does not modify any provision of Part I or Part II of the Registration Statement other than Item 16(a) of Part II as set forth below.

     

     

     

     

     

     

     

     

     

     2 

     

     

    PART II

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 16. Exhibits and Financial Statement Schedules.

     

    (a) Exhibits

     

    EXHIBIT INDEX

     

     

    Exhibit

    Number

      Exhibit Description   Form   SEC File No.   Exhibit
    No.
      Date   Filed
    Herewith
    5.1   Opinion of Brownstein Hyatt Farber Schreck, LLP.             X
                       
    5.2   Opinion of Cooley LLP.             X
                       
    23.1   Consent of Brownstein Hyatt Farber Schreck, LLP (included in Exhibit 5.1).             X
                       
    23.2   Consent of Cooley LLP (included in Exhibit 5.2).             X
                       
    24.1*   Power of Attorney (included on the signature page of the Registration Statement on Form S-1 (File No. 333-278188), as amended, filed with the Commission on March 22, 2024 and incorporated herein by reference).              

    __________________

      *   Previously filed.

     

     

     

     

     

     

     

     

     

     

     3 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in San Diego, California, on the 15th day of May, 2024.

     

     
    AETHLON MEDICAL, INC.
       
           
      By: /s/ JAMES B. FRAKES  
        James B. Frakes  
        Interim Chief Executive Officer  
        Chief Financial Officer  
        Chief Accounting Officer  
             

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

             
    Name   Title   Date
         

    /s/ JAMES B. FRAKES

    James B. Frakes

     

    Interim Chief Executive Officer

    Chief Financial Officer

    Chief Accounting Officer and Director

      May 15, 2024
         

    /s/ EDWARD G. BROENNIMAN*

    Edward G. Broenniman

      Chairman and Director   May 15, 2024
         

    /s/ NICOLAS GIKAKIS*

    Nicolas Gikakis

      Director   May 15, 2024
         

    /s/ ANGELA ROSSETTI*

    Angela Rossetti

      Director   May 15, 2024
         

    /s/ CHETAN S. SHAH*

    Chetan S. Shah, M.D.

      Director   May 15, 2024
         
    * Pursuant to power of attorney    

     

    By: /s/ JAMES B. FRAKES  
      James B. Frakes  
      Attorney in fact  

     

     

     

     4 

     

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD

    DatePrice TargetRatingAnalyst
    7/7/2025$1.50Neutral
    H.C. Wainwright
    6/25/2021$5.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AEMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

    Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr

    2/12/26 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026

    SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2025, at 4:15 p.m. ET on Thursday, February 12, 2026. Management will host a conference call on Thursday, February 12, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034

    2/4/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million

    SAN DIEGO, Dec. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 595,897 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 1,042,820 shares of common stock, in a private placement priced at-the-market under Nasdaq rules. The combined effective offering price for each share of common stock (or pre-funded warrant in-lieu thereof) and accompanying wa

    12/5/25 9:15:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    SEC Filings

    View All

    SEC Form 10-Q filed by Aethlon Medical Inc.

    10-Q - AETHLON MEDICAL INC (0000882291) (Filer)

    2/12/26 5:10:41 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AETHLON MEDICAL INC (0000882291) (Filer)

    2/12/26 4:15:44 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by Aethlon Medical Inc.

    DEFA14A - AETHLON MEDICAL INC (0000882291) (Filer)

    1/27/26 4:15:26 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Aethlon Medical with a new price target

    H.C. Wainwright resumed coverage of Aethlon Medical with a rating of Neutral and set a new price target of $1.50

    7/7/25 8:15:50 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Aethlon Medical with a new price target

    HC Wainwright & Co. reiterated coverage of Aethlon Medical with a rating of Buy and set a new price target of $9.00 from $5.00 previously

    6/25/21 6:10:29 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. initiated coverage on Aethlon Medical with a new price target

    HC Wainwright & Co. initiated coverage of Aethlon Medical with a rating of Buy and set a new price target of $5.00

    6/1/21 8:48:18 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Shah Chetan covered exercise/tax liability with 179 shares, decreasing direct ownership by 7% to 2,356 units (SEC Form 4)

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    1/2/26 6:43:21 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Director Gikakis Nicolas covered exercise/tax liability with 179 shares, decreasing direct ownership by 7% to 2,357 units (SEC Form 4)

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    1/2/26 6:42:37 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Director Broenniman Edward G covered exercise/tax liability with 89 shares, decreasing direct ownership by 3% to 2,807 units (SEC Form 4)

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    1/2/26 6:41:25 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Financials

    Live finance-specific insights

    View All

    Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

    Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr

    2/12/26 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026

    SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2025, at 4:15 p.m. ET on Thursday, February 12, 2026. Management will host a conference call on Thursday, February 12, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034

    2/4/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update

    Clinical and research progress continues alongside substantial cost reductions. Conference Call Today at 4:30 p.m. ET SAN DIEGO, Nov. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Compliance matters resolved, Aethlon remains in good standing with Nasdaq.Clinical Progress: Recruitment underway for Cohort 2 of the Australian oncology trial under amended protoc

    11/12/25 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Aethlon Medical, Inc. (Amendment)

    SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)

    1/13/22 10:30:14 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Aethlon Medical, Inc.

    SC 13G - AETHLON MEDICAL INC (0000882291) (Subject)

    6/15/21 10:01:32 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)

    2/22/21 9:53:48 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care